ARCHIVES

NCI Officials Open To Fine-Tuning Group Budgets As Advocates Chip Away At NCTN’s Façade

This article is from The Cancer Letter archive.

Vol. 40 No. 18 | May 2, 2014

Download PDF Visit The Full Archive

Related Articles

FDA approves a new cancer drug, Vidaza, and two sNDAs, without going to ODAC. A date with ODAC may signal a weak case for drug approval, recent approval data indicate.

May 28, 2004

Judge Hears Arguments In Fisher’s Privacy Act Suit Over Databases

January 19, 1996

Interview: Joseph Jacobs Claims “Political Extortion” By The “Harkinites”

October 14, 1994

Study Identifies Characteristics That Promote Early-Life NHL

May 25, 2012

Moffitt, Ohio State Form Network, Invite Major Cancer Centers to Join

May 30, 2014

House Committee Adds $73 Million To President’s NCI Budget, Only $13 Million Under Senate Figure

August 3, 1984